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Essentials
 In the double-blind (DB) part of HERCULES, caplacizumab was shown to be safe and 
effective 
 Following exacerbation during DB treatment, patients were treated with open-label 
caplacizumab 
 Caplacizumab was efficacious in patients with an exacerbation (mainly from the DB 
placebo group)
 The safety profile was consistent with the DB period (increased mucocutaneous bleeding)
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Summary
Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening 
autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor 
Nanobody®, is effective for treating aTTP episodes and is well tolerated.
Objectives and Methods: In the phase 3 HERCULES trial (NCT02553317), patients with aTTP 
received double-blind caplacizumab or placebo during daily therapeutic plasma exchange (TPE) 
and for ≥30 days thereafter. Patients who experienced an exacerbation while on blinded study drug 
treatment switched to receive open-label caplacizumab plus re-initiation of daily TPE. 
Exacerbations were defined as recurrence of disease occurring within 30 days after cessation of 
daily TPE.
Results: Thirty-one patients (placebo, n = 28; caplacizumab, n = 3) had an exacerbation during 
double-blind treatment. Twenty-eight patients switched to open-label caplacizumab (placebo, n = 
26; caplacizumab, n = 2); the three others discontinued upon exacerbation. Median time to platelet 
count response (≥150 x 109/L) was 3.49 days upon receiving caplacizumab. There were no deaths. 
During open-label treatment, further exacerbation or a major thromboembolic event (vena cava 
thrombosis) was experienced by one patient (3.6%) each. Consistent with the double-blind phase, 
the most frequent treatment-emergent adverse events were catheter site hemorrhage (28.6%), 
headache (21.4%), and epistaxis (17.9%).
Conclusions: These results suggest that caplacizumab was efficacious and well tolerated in 
patients with aTTP who experienced a disease exacerbation during double-blind treatment in 
HERCULES.
Key words: Caplacizumab; von Willebrand Factor; Plasma Exchange; Purpura, Thrombotic 
Thrombocytopenic; ADAMTS13 Protein
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1 | INTRODUCTION
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare thrombotic 
microangiopathy, characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, 
and organ ischemia, caused by a deficiency in ADAMTS13 activity [1,2]. The lack of 
ADAMTS13 activity means ultra-large multimers of von Willebrand factor (vWF) are no longer 
adequately processed and cleaved. This allows unrestrained vWF-mediated platelet adhesion in the 
microvasculature [3,4], which, if left untreated, is fatal in >90% of cases [3,5]. Although daily 
therapeutic plasma exchange (TPE) and immunosuppression has improved patient outcomes, acute 
mortality is still ~10 to 20% [6-12], and patients are at risk for irreversible organ damage 
[1,9,12,13]. In addition, 30 to 50% of patients experience disease exacerbations [14] (platelet 
count <150 x 109/L after initial recovery and within 30 days of last TPE [15]), which may require 
rehospitalization and resumption of TPE, and puts patients at risk for thrombotic events and death 
associated with active disease. aTTP also has a tendency to relapse (recurrent disease >30 days 
after last TPE14) if ADAMTS13 activity is severely deficient [1,4], with relapse rates of ~35 to 
40% [6,16] within the first 2 years, each relapse carrying a risk of morbidity and mortality.
Caplacizumab is a bivalent, humanized, single-variable-domain immunoglobulin or 
Nanobody® targeting the A1 domain of vWF [17], preventing interaction between vWF and 
platelets, and formation of microvascular thrombi. HERCULES (NCT02553317) was an 
international phase 3, randomized, double-blind, multicenter, placebo-controlled trial showing that 
caplacizumab was effective in treating aTTP, significantly shortening the time to normalization of 
platelet count versus placebo, and reducing the incidence of the composite endpoint (mortality, 
exacerbations and major thromboembolic events during the treatment period) by 74% and the 
overall number of TTP exacerbations/relapses by 67% [18]. In HERCULES, caplacizumab had an 
acceptable safety profile; mild-to-moderate mucocutaneous bleeding was the most frequent 
treatment-emergent adverse event (TEAE) [18]. Here we report the efficacy and safety outcomes 
of patients treated with open-label caplacizumab following an exacerbation during the double-
blind treatment phase.
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2 | METHODS
Detailed methods of the HERCULES study have been published [18]. Briefly, adults with 
clinically diagnosed aTTP and one prior TPE treatment were randomized to caplacizumab (10 mg 
intravenous loading dose followed by daily 10 mg subcutaneous doses) or placebo, plus daily TPE 
and glucocorticoids. Other immunosuppressive therapies were permitted as per local practice. 
Treatment with caplacizumab continued until 30 days after TPE cessation and could be extended, 
on a weekly basis (4 weeks maximum), based on the presence of risk factors for recurrence, such 
as persistent severely deficient ADAMTS13 activity (<10%). The HERCULES trial was 
conducted in accordance with the principles set out in the Declaration of Helsinki, Good Clinical 
Practice, and local regulations. All patients provided written, informed consent.
The HERCULES protocol specified that patients who experienced recurrent disease during 
the treatment period, defined as a new reduction in platelet count necessitating the re-initiation of 
TPE, were switched to receive open-label caplacizumab plus daily TPE, following the same 
schedule as the double-blind period (including treatment extension for up to 4 weeks) and 
maintaining the initial allocation blind. Treatment with caplacizumab beyond this time was not 
permitted and patients experiencing a second recurrence during open-label therapy were not 
retreated with open-label caplacizumab and received TPE and appropriate immunosuppression. 
Assessments, such as ADAMTS13 monitoring were conducted as during the double-blind 
treatment period, i.e., on a weekly basis following stop of daily TPE, and were used to guide the 
decision to extend therapy.  
Endpoints of interest included time to platelet count response, time to TPE cessation, 
exacerbations, relapses, major thromboembolic events, and mortality.
3 | RESULTS AND DISCUSSION
Twenty-eight patients in the placebo group and three in the caplacizumab group experienced an 
exacerbation during the double-blind treatment period (range: 2 to 25 days after daily TPE 
cessation). Twenty-five of 28 patients in the placebo group had ADAMTS13 activity <10% at the 
time of exacerbation, indicative of unresolved immunological disease (Table 1). In the A
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caplacizumab group, all three had an ADAMTS13 activity of <10%. Two patients had an infection 
likely contributing to the exacerbation, while the third was non-compliant with therapy (Table 1). 
Twenty-eight patients restarted daily TPE and received open-label caplacizumab (placebo: n 
= 26; caplacizumab: n = 2) without breaking the initial-treatment blind; three discontinued study 
drug treatment upon exacerbation. Of these, 26 patients received corticosteroids during the open-
label TPE period. Of these 26, 11 patients also received rituximab (42.3%) during the open-label 
daily TPE period; this proportion was higher than that seen in the double-blind daily TPE period 
(12 [17.1%] patients in the caplacizumab arm and 21 [29.6%] patients in the placebo arm), 
suggesting that investigators were more likely to intensify immunosuppressive therapy after an 
exacerbation.
The median times from first intravenous injection of study drug to platelet count response 
(3.49 days) and to daily TPE cessation (6.0 days) in the open-label group (Table 1) were consistent 
with results of the caplacizumab-treated patients in the randomized phase 2 TITAN study [19] and 
the double-blind caplacizumab group of the HERCULES study [18].
One patient had an exacerbation while receiving open-label treatment (normal ADAMTS13 
activity [60%] and signs of infection), while two others had an exacerbation after prematurely 
stopping open-label treatment while having low ADAMTS13 activity, hence being at risk for 
recurrence (reasons for treatment discontinuation: planned splenectomy and serious adverse event 
[SAE] of dyspnea). A fourth patient relapsed after completion of open-label caplacizumab 
treatment (Table 1). All three patients who had an exacerbation or relapse after caplacizumab 
cessation had ADAMTS13 activity <10% at the time of cessation (range of open-label treatment 
duration: 3 to 65 days; exacerbation/relapse occurred within 8 to 10 days of caplacizumab 
treatment cessation). This is consistent with relapses observed in the follow-up period after 
double-blind treatment [18], demonstrating that caplacizumab can protect patients at risk from 
recurrence and indicating the need to continue treatment with caplacizumab during optimization of 
immunosuppressive therapy, until resolution of underlying immunological disease is achieved (i.e. 
partial or complete normalization of ADAMTS13 activity).
One patient experienced an adjudicated major thromboembolic event, vena cava thrombosis, 
during open-label caplacizumab treatment. Platelet counts at the time of the event were 137x109/L. A
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The event was considered mild in severity and unrelated to study drug. Treatment was initiated 
with concomitant heparin (for 2 days) and thereafter enoxaparin sodium, and the event resolved 34 
days after onset without interrupting open-label caplacizumab treatment. None of the patients 
treated with open-label caplacizumab died. 
The median duration of exposure to open-label caplacizumab was 36.5 days (range 3 to 65). 
Twenty-five patients (89.3%) reported at least one TEAE during open-label treatment; most 
TEAEs were of mild-to-moderate severity (Table 2). Seven patients (25%) had an SAE during 
open-label treatment (Table 2). Bleeding-related TEAEs were reported in 22 patients (78.6%), the 
most frequent being catheter site hemorrhage (28.6%), epistaxis (17.9%) and gingival bleeding 
(14.3%). All bleeding-related TEAEs were of mild-to-moderate severity, and the majority resolved 
without therapeutic intervention.
Overall, the safety profile of open-label caplacizumab was consistent with that observed in 
TITAN [19] and in the double-blind period in HERCULES [18]. A similar proportion of patients 
receiving caplacizumab in the double-blind and open-label periods of HERCULES experienced 
TEAEs (95.8% vs 89.3%), and mucocutaneous bleeding was a common bleeding-related TEAE in 
TITAN and both phases of HERCULES [18,19]. Thus, caplacizumab in patients receiving 
treatment for an exacerbation demonstrated an acceptable safety profile consisting of mainly mild-
to-moderate mucocutaneous bleeding, and no new safety signals were identified.
Exacerbations of aTTP not only re-expose patients to the increased risk of morbidity and 
mortality [16,20], they also lead to readmission and resumption of daily TPE, and its 
complications [21,22]. Thus, prevention of exacerbations is paramount. In patients who experience 
an exacerbation, prompt resolution of the episode is required to prevent further complications. 
Exacerbation rates during the double-blind period of HERCULES was substantially lower in the 
caplacizumab versus placebo group (4% vs 38%) [18], and was associated with a significant 
reduction in the need for ongoing TPE and hospitalization. Patients experiencing an exacerbation, 
mainly from the placebo group, were promptly treated with open-label caplacizumab, and this 
resulted in similar positive outcomes as seen in the double-blind period of HERCULES, namely a 
fast normalization of platelet counts, and continued protection against further exacerbations [18]. 
No patients died during open-label treatment, together with an acceptable safety profile. These 
results from the open-label phase of HERCULES thus confirm the efficacy and safety of A
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caplacizumab in controlling platelet consumption and aTTP propagation, even when patients are 
in an exacerbating state, and demonstrate improved outcomes for aTTP patients.  
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TABLES
Table 1 Patient disposition, baseline characteristics, and efficacy outcomes in patients treated with 
open-label caplacizumab
Patient disposition
Experienced an exacerbation (N = 145), n (%) 31 (21.4%)
Double-blind placebo group (N = 73)
Switched to open-label caplacizumab
Double-blind caplacizumab group (N = 72)
Switched to open-label caplacizumab
28 (38.4)
26 (35.6)
3 (4.2)
2 (2.8)
Completed open-label therapy (N = 28), n (%) 20 (71.4)
Treatment until 30 days post daily TPE
At least one week of treatment extensiona
13 (46.4)
7 (25.0)
Premature discontinuations (N = 28), n (%) 8 (28.6)
Withdrawal of consent 3 (10.7)
Physician decision
Lost to follow up
Non-compliance 
Adverse event
2 (7.1)
1 (3.6)
1 (3.6)
1 (3.6)
Exposure time, median, days (range) 36.5 (3-65)
Baseline characteristics at time of exacerbation N = 28
Platelet counts (x109/L), mean (range)
Patients from double-blind placebo group (N = 24)
Patients from double-blind caplacizumab group (N = 2)
60.7 (13-149)
92.5 (71-114)
LDH (U/L), mean (range) 
cTnI (µg/L), mean (range)
Serum creatinine(µmol/L), mean (range)
ADAMTS13 activity <10%, n
403 (138-1135)
0.044 (0.010-0.298)
100.3 (35-448)
Patients from double-blind placebo group (N = 28)
Patients from double-blind caplacizumab group (N = 3)
25b
3c
Efficacy endpoints N = 28
Median time from first intravenous injection to platelet count 
response,d days  (95% CI) [25% percentile, 75% percentile]
3.49 (2.81, 4.81)
[2.70, 5.56]
Median time to daily TPE cessation, days (95% CI) 6.0 (5.0, 7.0)A
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Exacerbation during open-label treatment, n (%)
Exacerbation after cessation of open-label treatment, n (%)
Relapse after completing open-label treatment, n (%)
Deaths, n (%)
Major thromboembolic event, n (%)
1 (3.6)e
2 (7.1)f
1 (3.6)g
0 (0)
1 (3.6)h
Abbreviations: CI, confidence interval; cTnI, cardiac troponin I; LDH, lactate dehydrogenase; 
TPE, therapeutic plasma exchange; TTP, thrombotic thrombocytopenic purpura.
aIn one patient the treatment was extended for 2 weeks, in one patient for 3 weeks, and in five 
patients for 4 weeks (the maximum treatment extension allowed per protocol). 
bOf the placebo patients with ADAMTS13 ≥10%, one patient had a reported “suspected drug 
induced/infection-related TTP exacerbation” (verbatim term), suggestive of an infection-induced 
thrombocytopenia, and was corroborated by a normal ADAMTS13 of 78% at the time of 
exacerbation. Two other placebo patients had an ADAMTS13 of 11% and 64%.
cIn two patients, an infection may have triggered the thrombocytopenia: in one patient the TTP 
exacerbation was reported as ‘Suspected infection associated TTP exacerbation’, with an adverse 
event of ‘device-related sepsis (catheter-associated bloodstream infection’ reported on the day 
preceding the exacerbation. The other patient also had findings suggestive of an infection (i.e. 
increase in C-reactive protein levels and increases in leukocytes and neutrophils). The third patient 
was non-compliant with therapy while having low ADAMTS13 (patient discontinued at time of 
exacerbation).
dPlatelet response defined as an initial platelet count ≥150×109/L with subsequent stop of daily 
TPE within 5 days.
ePatient was clinically well and had mild thrombocytopenia at 149 x 109/L, while ADAMTS13 
activity was normal at 60% and leukocyte and neutrophil counts were mildly elevated, suggestive 
of subclinical infection. Open-label caplacizumab was permanently withdrawn, as per protocol.
fADAMTS13 activity was <10% at the time of cessation of open-label caplacizumab; treatment 
was discontinued for a planned splenectomy in one patient (after receiving 3 days of open-label 
treatment) and for an SAE of dyspnea in another patient (after receiving open-label treatment for 
the duration of daily TPE and 7 days thereafter).
gADAMTS13 activity was <10% at the time of completion of open-label caplacizumab (therapy 
was maximally extended for 4 additional weeks, as allowed per protocol)
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hVena cava thrombosis (verbatim: “affixing intraluminal thrombotic of posterior wall of inferior 
cava vein, suspected thrombosis”), considered mild in severity and not related to study drug by the 
investigator.
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Table 2 Overview of treatment-emergent adverse events occurring in patients treated with open-
label caplacizumab
Open-label caplacizumab 
(n = 28), n (%)
TEAE overview, patients with:
≥1 TEAE 25 (89.3)
≥1 Serious AE 7 (25.0)
≥1 TEAE leading to death 0
≥1 TEAE leading to study drug withdrawal 1 (3.6)
≥1 TEAE considered at least possibly treatment-related 20 (71.4)
≥1 Serious AE considered at least possibly treatment-related 2 (7.1)
TEAE severity, patients with:
≥1 Mild TEAE 13 (46.4)
≥1 Moderate TEAE 9 (32.1)
≥1 Severe TEAE 3 (10.7)a
Incidence of individual TEAEs
Serious AEs
aTTP 4 (14.3)b
Upper gastrointestinal hemorrhage 1 (3.6)
Dyspnea 1 (3.6)
Seizure 1 (3.6)
Erythematous rash 1 (3.6)
Most frequent TEAEs (reported in ≥10% of patients)
Catheter site hemorrhage 8 (28.6)
Headache 6 (21.4)
Epistaxis 5 (17.9)
Gingival bleeding 4 (14.3)
Constipation 4 (14.3)
Diarrhea 4 (14.3)
Abdominal pain upper 4 (14.3)
Rash 4 (14.3)
aTTP 4 (14.3)
Anemia 4 (14.3)
Dyspnea 3 (10.7)A
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Petechiae 3 (10.7)
Ecchymosis 3 (10.7)
Arthralgia 3 (10.7)
Abbreviations: AE, adverse event; aTTP, acquired thrombotic thrombocytopenic purpura; TEAE, 
treatment-emergent adverse event.
aSevere TEAEs were anemia, dyspnea (temporally related to the removal of the central venous 
line, and suspected to have been caused by an air embolism and judged unrelated to study drug), 
and pruritus (judged to be unrelated to study drug and related to therapeutic plasma exchange by 
the investigator).
bOne patient experienced recurrence of TTP while receiving open-label treatment; three patients 
had a recurrence of TTP following cessation of caplacizumab. All three patients had an 
ADAMTS13 level of <10% at the time of treatment cessation. 
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